Friday 16 October 2026
Afternoon Edition
ZOTPAPER

News without the noise

ZOTPAPER
Startups

Intero Biosystems wins Startup Battlefield at TechCrunch Disrupt 2026

Denver organoid startup takes the $100,000 prize; Australian scam-baiting AI firm Apate named runner-up

By LineZotpaper
Published
Read Time2 min
Sources2 outlets
Intero Biosystems, a Denver-based startup growing miniature human intestines for drug testing, has won the Startup Battlefield at TechCrunch Disrupt 2026 in San Francisco, taking home the Startup Battlefield Cup and $100,000. The company beat out 19 other competitors, with Australian anti-scam startup Apate finishing as runner-up.

Intero Biosystems was one of 20 startups selected from the Startup Battlefield 200 to pitch live over three days this week in San Francisco. Each company presented a live demo in front of venture capitalists and tech leaders, with TechCrunch editors narrowing the field to five finalists: Apate, Flox Intelligence, Intero Biosystems, Industrial Next, and Satlyt.

The final five then pitched to a panel of judges including Alexa von Tobel of Inspired Capital, Chi-Hua Chien of Goodwater Capital, Dayna Grayson of Construct Capital, Karl Alomar of M13, and Stacy Brown-Philpot of Cherryrock Capital.

Founded by Charlie Childs and Madeline Eiken and spun out of the University of Michigan, Intero develops one-millimetre human intestinal organoids: lab-grown tissue that mimics the gut, offering a way to study how drugs and other compounds might affect the human body before they are tested in people. Its flagship product, GastroScreen, is sold to pharmaceutical, biotech, food, and chemical companies.

Runner-up Apate, founded by Dali Kaafar out of research at Macquarie University in Sydney, deploys thousands of AI agents that masquerade as innocent victims to bait fraudsters. The agents answer scam calls, respond to suspicious messages and emails, follow phishing links, and join social media groups, while customers receive an insights portal offering intelligence and analytics on scams targeting their end users, employees, and brands.

Intero and Apate now join past Startup Battlefield winners and finalists including Trello, Discord, Cloudflare, and Mint. More than 1,700 companies have participated in the program, collectively raising over $30 billion in funding with more than 200 successful exits.

§

Analysis

Why This Matters

  • Intero's win highlights organoids as a growing alternative to animal testing, with drugmakers under pressure to better predict how compounds behave in humans before trials.
  • Apate's runner-up finish puts Australian-developed scam-baiting AI in front of global investors at a time when fraud remains a costly, large-scale problem.
  • Startup Battlefield has a track record of surfacing well-known companies, so the progress of this year's cohort is worth watching.

Background

Organoids are small, lab-grown structures that mimic the behaviour of real organs, used in research to test how drugs and other compounds respond in human-like tissue. TechCrunch's Startup Battlefield is a long-running pitch competition held at its annual Disrupt conference, where early-stage companies demo live before investor judges and compete for the Startup Battlefield Cup and a cash prize. Past participants have gone on to become widely known companies, though most entrants remain early stage.

Key Perspectives

Intero Biosystems: Argues that lab-grown gut tissue gives pharmaceutical, biotech, food, and chemical companies a better way to study how compounds affect the human body before people are exposed, with GastroScreen as its commercial entry point. Apate: Positions itself on the fraud-intelligence side, arguing that AI agents can absorb scam traffic at scale by letting fraudsters target decoys instead of real victims, while feeding actionable data back to customers. Judges and investors: The final panel, made up of venture investors, will ultimately weigh whether each startup has defensible technology, a clear market, and the team to execute. Critics and skeptics: Organoid technology is still maturing, and open questions remain about how closely lab-grown tissue replicates human biology, how regulators will treat it as evidence, and whether it will meaningfully displace existing testing methods.

What to Watch

  • Whether Intero signs major pharmaceutical or biotech customers for GastroScreen in the coming year.
  • Apate's path after its high-profile finish, particularly any funding round or enterprise deals.
  • How many startups from the 2026 Battlefield cohort convert their appearances into investment, given the program's strong alumni track record.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workSubscribe